Trials / Terminated
TerminatedNCT04488575
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Evelo Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
Detailed description
This is a randomized, placebo-controlled clinical study to assess the safety and efficacy of EDP1815 in patients hospitalized with COVID-19 infection. The study is designed to evaluate the efficacy of EDP1815 at reducing time to resolution of symptoms, preventing progression of COVID-19 symptoms and preventing COVID-Related Complications (CRC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDP1815 | EDP1815 is an orally administered monoclonal microbe |
| DRUG | Placebo | Placebo oral capsule |
Timeline
- Start date
- 2020-08-26
- Primary completion
- 2021-05-16
- Completion
- 2021-05-19
- First posted
- 2020-07-28
- Last updated
- 2022-12-19
- Results posted
- 2022-12-19
Locations
4 sites across 2 countries: United States, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04488575. Inclusion in this directory is not an endorsement.